



Aviragen Therapeutics, Inc.  
Investor Relations Department  
2500 Northwinds Parkway  
Suite 100  
Alpharetta, GA 30009  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AVIR**

Last Trade:	0.76
Trade Time:	3:59 PM ET Oct 20, 2017
Change:	0.04  (+5.657%)
Day Range	0.71 - 0.78
52-Week Range	0.43 - 1.60
Volume	337,186

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: varendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplavovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papill... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

*Aug 31, 2017*

[Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results](#)

*May 4, 2017*

[Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results](#)

*Apr 4, 2017*

[Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update](#)

*Feb 13, 2017*

[Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Varendavir](#)

*Feb 2, 2017*

[Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results](#)

## Financials [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

*Sep 1, 2017*

[Annual Report \(10-K\)](#)

*Sep 27, 2016*

[Proxy Statement \(DEF 14A\)](#)

*May 8, 2017*

[Quarterly Report \(10-Q\)](#)

*Feb 6, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)